Search
  • 網站搜尋
亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。
返回搜索結果

Permanent Transplant Tolerance by Induction of Modified T-Cell Regulation


總結

Lead Inventors: Hong Jiang, M.D., Ph.D. and Leonard Chess, M.D.Problem or Unmet Need:The human immune response, differentiating self from other, while critical to our health and survival, can itself become a hindrance, even life threatening when a tissue transplant is necessary. The regimen of treatment for transplant recipients typically consists of immuno-suppressive therapy to mute the body's natural response to foreign invaders. This approach leaves the patient compromised and susceptible to infection, rendering everyday pathogens life threatening. There is a clear need for a more precise, targeted means of achieving graft tolerance while preserving overall immune function. The invention is a treatment protocol for inducing transplant tolerance without inhibiting global immune function. The treatment relies on insight into the stages of mounting immune response and the checks and balances the immune system employs to manage immune response, particularly autoimmunity, to establish permanent graft acceptance without need for lifelong immunosuppressive therapy. There are two stages involved. In the first stage acute graft rejection is circumvented through transfusion of donor cells, and subsequent transformation of donor specific high avidity T-Cells response for acute rejection. In the second stage long term graft rejection is managed by down regulating the moderate avidity T-Cells responsible for chronic graft rejection, employing the body's own regulatory strategies for regulating auto-immunity. The result is tolerance of the graft as if it were native tissue while preserving overall immune functionality.


技術優勢

Eliminates need for long term immunosuppressive therapy Preserves critical immune function, while maintaing graft tolerance Risk of thromboembolism, a common side effect of acute phase therapy is managed via in patient administration of the first phase and use of anti-coagulants Subsequent acute rejection periods are prevented due to deletion of high avidity response


技術應用

Therapy to establish donor tissue tolerance in transplant recipients without use of long term immunosuppressives Therapy to treat CD8+ T-Cell mediated auto-immune conditions


詳細技術說明

The invention is a treatment protocol for inducing transplant tolerance without inhibiting global immune function. The treatment relies on insight into the stages of mounting immune response and the checks and balances the immune system employs to ma...


國家/地區

美國

欲了解更多信息,請點擊 這裡
Business of IP Asia Forum
桌面版